Ticker > Company >

Solara Active Pharma share price

Solara Active Pharma Sciences Ltd.

  83.99 K   153   26 NSE: SOLARA BSE: 541540 SECTOR: Pharmaceuticals & Drugs

678.00
-38.00 (-5.31%)
BSE: 05 Oct 04:01 PM

Price Summary

Today's High

₹ 722.85

Today's Low

₹ 674

52 Week High

₹ 768

52 Week Low

₹ 422.85

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 3271.38 Cr.

Enterprise Value

₹ 3882.25 Cr.

No. of Shares

4.83 Cr.

P/E

0

P/B

2.57

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  263.96

CASH

₹ 4.16 Cr.

DEBT

₹ 615.03 Cr.

Promoter Holding

41.93 %

EPS (TTM)

₹  -0.16

Sales Growth

6.64%

ROE

-0.62 %

ROCE

4.65%

Profit Growth

-570.37 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.64%
3 Year-1.76%
5 Year-3.27%

Profit Growth

1 Year-570.37%
3 Year18.74%
5 Year-150.48%

ROE%

1 Year-0.62%
3 Year-15.74%
5 Year-10.49%

ROCE %

1 Year4.65%
3 Year-2.2%
5 Year-1.1%

Debt/Equity

0.492

Price to Cash Flow

21.4

Interest Cover Ratio

0.9232

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 41.93 37.11
Mar 2026 42.00 31.57
Dec 2025 42.00 26.04
Sep 2025 42.01 35.32
Jun 2025 42.01 38.95
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 18.7372379744244% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 44.8727 days.

 Limitations

  • The company has shown a poor revenue growth of -1.75832397551976% for the Past 3 years.
  • Company has a poor ROE of -15.7434% over the past 3 years.
  • Promoter pledging has increased from 31.5701017646881% to 37.11% in 1 quarter.
  • Company has a poor ROCE of -2.19956666666667% over the past 3 years
  • Company has low Interest coverage ratio of 0.9232.
  • Company has contingent liabilities of 563.73 Cr.
  • Tax rate is low at 0.
  • Promoter pledging is high as 37.11%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 319.15 313.54 349 387.29 381.6
Total Expenditure 262.12 278.79 311.65 329.74 319.59
Operating Profit 57.03 34.75 37.35 57.55 62.01
Other Income 0.98 0.49 0 4.42 1.92
Interest 23.9 20.83 22.45 27.06 20.23
Depreciation 23.58 24.49 25.57 26.04 26.71
Exceptional Items 0 0 -6.75 0.86 0
Profit Before Tax 10.53 -10.08 -17.42 9.73 16.99
Tax 0 0 0 0 0
Profit After Tax 10.53 -10.08 -17.42 9.73 16.99
Adjusted EPS (Rs) 2.37 -2.27 -3.92 2.19 3.54

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 1268.34 1443.81 1288.92 1283.76 1368.98
Total Expenditure 1187.99 1309.77 1383.98 1079.92 1182.3
Operating Profit 80.35 134.04 -95.06 203.84 186.68
Other Income 18.76 22.14 5.37 9.14 5.89
Interest 75.27 90.06 105.97 114.81 94.24
Depreciation 112.01 110.9 103.03 99.25 99.68
Exceptional Items -3.49 0 -189.64 0 -5.89
Profit Before Tax -91.66 -44.78 -488.33 -1.08 -7.24
Tax -33.1 -22.57 78.54 0 0
Net Profit -58.56 -22.21 -566.87 -1.08 -7.24
Adjusted EPS (Rs.) -14.99 -5.69 -145.13 -0.27 -1.63

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 36 36 36 40.25 44.51
Total Reserves 1491.05 1467.13 901.42 1055.96 1210.93
Borrowings 283.04 235.1 105.83 113.86 60.94
Other N/C liabilities 16.18 -17.94 65.7 76.96 72.68
Current liabilities 1056.03 1096.12 1237.65 938.07 887.53
Total Liabilities 2882.3 2816.41 2346.6 2225.1 2276.59
Assets
Net Block 1325 1333.22 1258.7 1184.52 1230.91
Capital WIP 238.65 238.47 256.37 280.05 204.79
Intangible WIP 0 0 0 0 0
Investments 14.77 16.05 14.25 1.7 1.63
Loans & Advances 54.38 28.5 23.76 27.52 30.27
Other N/C Assets 9.63 9.3 2.87 2.71 0.3
Current Assets 1239.87 1190.87 790.65 728.6 808.69
Total Assets 2882.3 2816.41 2346.6 2225.1 2276.59
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations -91.66 -44.78 -488.33 -1.08 -7.24
Adjustment 181.98 186.88 405.79 212.16 200.68
Changes in Assets & Liabilities -314.04 0.36 192.57 2.62 -38.43
Tax Paid -18.05 13.71 0.92 -0.9 -2.12
Operating Cash Flow -241.77 156.17 110.95 212.8 152.89
Investing Cash Flow -243.08 -81.13 -4.66 -36.83 -50.14
Financing Cash Flow 333.59 -112.76 -106.52 -180.48 -102.56
Net Cash Flow -151.26 -37.72 -0.23 -4.51 0.19

Corporate Actions

Investors Details

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY22
Concall Q3FY24
Concall Q3FY22
Concall Q2FY24
Concall Q1FY24
Concall Q1FY24
Concall Q1FY23
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY22
Presentation Q4FY21
Presentation Q3FY25
Presentation Q2FY22
Presentation Q2FY21
Presentation Q2FY20
Presentation Q1FY21

Company News

Solara Active Pharma Stock Price Analysis and Quick Research Report. Is Solara Active Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Solara Active Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Solara Active Pharma has a PE ratio of -4186.14718614719 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Solara Active Pharma has ROA of -0.3217% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Solara Active Pharma has a Current ratio of 0.9112.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Solara Active Pharma has a ROE of -0.618%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Solara Active Pharma has a Debt to Equity ratio of 0.492 which means that the company has low proportion of debt in its capital.

  • Sales growth: Solara Active Pharma has reported revenue growth of 6.6383% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Solara Active Pharma for the current financial year is 13.6364300428056%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Solara Active Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Solara Active Pharma is Rs -0.1617. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Solara Active Pharma in Ticker for free. Also, one can get the intrinsic value of Solara Active Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Solara Active Pharma FAQs

Q1. What is Solara Active Pharma share price today?
Ans: The current share price of Solara Active Pharma is Rs 676.9.

Q2. What is the market capitalisation of Solara Active Pharma?
Ans: Solara Active Pharma has a market capitalisation of Rs 3266.07715728 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Solara Active Pharma?
Ans: The PE ratio of Solara Active Pharma is -4186.14718614719 and the P/B ratio of Solara Active Pharma is 2.56436872356643, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Solara Active Pharma share?
Ans: The 52-week high share price of Solara Active Pharma is Rs 767.9, and the 52-week low share price of Solara Active Pharma is Rs 422.

Q5. Does Solara Active Pharma pay dividends?
Ans: Currently, Solara Active Pharma does not pay dividends. Dividend yield of Solara Active Pharma is around 0%.

Q6. What are the face value and book value of Solara Active Pharma shares?
Ans: The face value of Solara Active Pharma shares is Rs 10, while the book value per share of Solara Active Pharma is around Rs 263.9636. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Solara Active Pharma?
Ans: Solara Active Pharma has a total debt of Rs 615.03 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Solara Active Pharma?
Ans: The ROE of Solara Active Pharma is -0.618% and ROCE of Solara Active Pharma is 4.649%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Solara Active Pharma a good buy for the long term?
Ans: The Solara Active Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Solara Active Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Solara Active Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Solara Active Pharma’s financials?
Ans: You can review Solara Active Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Solara Active Pharma
X